reports
NGM Bio Announces Closing of Tender Offer
NGM Bio Announces Closing of Tender Offer SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that Atlas Neon Parent, Inc. (“Parent”), an affiliate of The Column Group, LP (“TCG”), through its wholly-owned subsidiary Atlas Neon Merger Sub, Inc. (“Merger Sub”), has successfully completed the previously announced cash tender offer to acquire all outstanding shares of NGM Bio not held by affiliates of TCG and certain oth...
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ong...
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have be...
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter...
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results --Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA® (pembrolizumab) with expected completion of enrollment in the second quarter of 2024-- --Announced ongoing toxicology activities intended to support initiation of a potential proof-of-concept study of NGM120, a GDF15/GFRAL antagonist, for the treatment of hyperemesis gravida...
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger wit...
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt from The Column Group of a non-binding expression of interest in purchasing shares in a going-private transactionBased on a thorough exploration and review of strategic and financial alternatives, a Special Committee of independent and disinterested directors unanimously recommends the transaction SAN FRANCISCO, Feb. 26, 2...
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a corporate panel discussion on novel oncology targets at the Cowen 44th Annual Health Care Conference on Tuesday, March 5th, at 9:10 am ET. A live webcast of the presentation will be available under the Investors and M...
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology ...
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Jean-Frédéric Viret, Ph.D., Chief Financial Officer, will participate in the B. Riley Securities 4th Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Thursd...
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Ad...
NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need Encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer (CRC), in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody, in combination with KEYTRUDA® (pembrolizumab) Aldafermin, an engineered FGF19 analog, has been granted Orphan Drug Designation by the FDA for the treatment of primary sclerosin...
- Jonathan Moreland
HRTX HERON THERAPEUTICS INC
COMM COMMSCOPE HOLDING CO. INC.
CVV CVD EQUIPMENT
NRP NATURAL RESOURCE PARTNERS L.P.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
NGM NGM BIOPHARMACEUTICALS
PTON PELOTON INTERACTIVE
ALTG INC.
ADV ALTA EQUIPMENT GROUP INC.
RPTX ADVANTAGE SOLUTIONS INC (A)
FTCI REPARE THERAPEUTICS
PCT FTC SOLAR
HYLN INC.
AGILITI INC.
PURECYCLE TECHNOLOGIES INC
HYLIION HOLDINGS CORP.
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of ...
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® --As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a statistically significant reduction in Enhanced Liver Fibrosis (ELF) score compared to placebo after 48 weeks of treatment-- --ELF, an FDA-approved non-invasive blood test, can be used to predict liver-related events in patients with nonalcoholic steatohepatitis (NASH) and compensated cirrhosis-- --Dose-dependent improve...
NGM Bio to Participate in Upcoming Investor Conferences
NGM Bio to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference and will present an overview of the company and provide a business update. Management will also be available for investor meetings at the upcoming ...
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Busi...
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights --Jean-Frédéric Viret, Ph.D., has been appointed as Chief Financial Officer effective November 3, 2023-- --Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438-- --Selected for an oral plenary presentation of data from Phase 2b ALPINE 4 trial of aldafermin in compensated cirrhosis (F4) due to NASH at upcoming AASLD The Liver Meeting®-- --Reported $166.0 million in cash, cash equivalents and marketable securities as of September 30, 2023, with expected cash runway into...
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPI...
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting® SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that an abstract related to comprehensive results from the company’s Phase 2b ALPINE4 trial of aldafermin in patients with compensated cirrhosis (liver fibrosis stage 4, or, F4) due to...
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Bus...
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights --Announced positive data from Phase 2 investigator-sponsored trial of aldafermin for the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and bile acid malabsorption (BAM)-- --Announced topline positive data from Phase 2b ALPINE 4 trial of aldafermin; study met its primary endpoint in patients with compensated cirrhosis (F4) due to NASH-- --Continued to progress myeloid checkpoint solid tumor programs: NGM707, NGM831 and NGM438-- --Reported $193.5 million in cash,...
NGM Bio to Participate in Upcoming Investor Conferences
NGM Bio to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and provide a business update at the following upcoming investor conferences. Cowen 4th Annual Oncology Innovation SummitWednesday, May 31, 2023, 2:00 pm ET Jefferies Healthcare ConferenceThursday, June 8...
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Spons...
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023 Aldafermin demonstrated statistically significant reductions in serum 7αC4 (a marker of bile acid synthesis) and fecal bile acids versus placebo in patients with idiopathic BAM with IBS-DAround 25-50% of patients with diarrhea-predominant IBS (or IBS-D) have evidence of BAMFindings complete an extensive clinical data package that NGM Bio will lev...
NGM Bio Reports First Quarter 2023 Financial Results and Provides Busi...
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data Phase 2b ALPINE 4 trial met its primary endpoint, demonstrating a statistically significant improvement in Enhanced Liver Fibrosis (ELF) score at 48 weeks versus baseline in patients with compensated cirrhosis (F4) due to NASH treated with 3 mg of aldafermin, an engineered FGF19 analog product candidate, compared to patients treated with placeboInitiated the first two Phase 2b expansion cohorts in the Phase 1/2 trial evaluating NGM707, an ILT2/ILT4 antagonist antibody produ...
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in the Cowen 43rd Annual Health Care Conference as part of the Novel Oncology Targets Panel and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Tuesday, March 7th, at 9:10 ...
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Fu...
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results --Presented preliminary findings from the Phase 1a monotherapy dose escalation portion of the ongoing Phase 1/2 trial of NGM707 in patients with advanced or metastatic solid tumors at the ESMO I-O Annual Congress-- --Initiated a Phase 1b cohort of the ongoing Phase 1/1b trial evaluating NGM438 in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with advanced or metastatic solid tumors-- SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmace...
- Jonathan Moreland
PNC PNC FINANCIAL SERVICES GROUP INC.
WLDN WILLDAN GROUP
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
MACK MERRIMACK PHARMACEUTICALS INC
INTC INTEL CORPORATION
HSKA HESKA CORPORATION
FMNB FARMERS NATIONAL BANC CORP.
FFIN FIRST FINANCIAL BANKSHARES INC
FCF FIRST COMMONWEALTH FINANCIAL CORPORATION
EQR EQUITY RESIDENTIAL
EOG EOG RESOURCES INC.
CPRX CATALYST PHARMACEUTICALS
CMTL COMTECH TELECOMMUNICATIONS CORP.
CHTR CHARTER COMMUNICATIONS INC. CLASS A
CAMP CALAMP CORP.
CALX CALIX NETWORKS
BANF BANCFIRST
NEWT NEWTEK BUSINESS SERVICES INC.
CVV CVD EQUIPMENT
TREE LENDINGTREE INC.
SMMF SUMMIT FINANCIAL GROUP INC.
CDZI CADIZ INC.
JNCE JOUNCE THERAPEUTICS
APPN APPIAN
DCPH DECIPHERA PHARMACEUTICALS INC.
MPB MID PENN BANCORP INC.
OPTN OPTINOSE
GIM TEMPLETON GLOBAL INCOME FUND
SRRK SCHOLAR ROCK HOLDING CORPORATION
OPBK OP BANCORP
NGM NGM BIOPHARMACEUTICALS
FULC FULCRUM THERAPEUTICS
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
ZYME ZYMEWORKS INC.
PGEN PRECIGEN INC
NREF NEXPOINT REAL ESTATE FINANCE
ZI INC.
RILY ZOOMINFO TECHNOLOGIES INC.
ALVR B. RILEY FINANCIAL
GMED ALLOVIR
HOWL GENOMED INC
MYO WEREWOLF THERAPEUTICS
XOS INC.
TRST MYOMO
APLD XOS INC
EMO TRUSTCO BANK CORP NY
HSAQ APPLIED BLOCKCHAIN INC
MSGM CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
HEALTH SCIENCES ACQUISITIONS CORP 2
MOTORSPORT GAMES INC
- Jonathan Moreland
CHTR CHARTER COMMUNICATIONS INC. CLASS A
TREE LENDINGTREE INC.
APPN APPIAN
MPB MID PENN BANCORP INC.
GLG CHINA COMMERCIAL CREDIT
NGM NGM BIOPHARMACEUTICALS
BDSX BIODESIX
COIN COINBASE GLOBAL
XMTR INC.
EMO XOMETRY
TEAM INC.
CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
ATLASSIAN CORPORATION
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.